ReviewCureus2025
Pathophysiology of Primary Budd-Chiari Syndrome: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Budd-Chiari syndrome (BCS) is a rare hepatic vascular disorder characterized by obstruction of hepatic venous outflow, leading to sinusoidal congestion, portal hypertension, and centrilobular necrosis - a classical model of postsinusoidal portal hypertension. This review provides an integrated analysis of the pathophysiology of BCS according to the site of obstruction (major hepatic veins, small/centrilobular veins, or inferior vena cava), describing how increased sinusoidal pressure, reduced portal flow, and compensatory mechanisms (intrahepatic collaterals, caudate lobe hypertrophy, and arterialization) shape clinical phenotypes that range from asymptomatic to acute, subacute, and chronic forms. The review highlights the etiopathogenesis of prothrombotic states - particularly myeloproliferative neoplasms (predominantly JAK2 V617F), hereditary thrombophilias, and acquired conditions, such as antiphospholipid syndrome and paroxysmal nocturnal hemoglobinuria - as well as the contributory role of pregnancy, the puerperium, and systemic diseases. It also discusses epidemiologic variability between Western and Asian populations and its clinical implications. Finally, it emphasizes a diagnostic approach based on Doppler ultrasonography (supported by computed tomography (CT) or magnetic resonance imaging (MRI)) and a stepwise management strategy prioritizing early anticoagulation, treatment of portal hypertension complications, decompression via transjugular intrahepatic portosystemic shunt (TIPS), and liver transplantation in selected cases. Understanding these mechanisms is key to improving diagnostic accuracy and guiding therapeutic decisions that have substantially enhanced patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.